Article Information
History
- October 13, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Pierre-Olivier Gaudreault, PhD1,
- Akarsh Sharma, MS1,
- Abhishek Datta, PhD2,
- Ester M. Nakamura-Palacios, MD, PhD3,
- Sarah King, BSc1,
- Pias Malaker, MSc1,
- Ariella Wagner, MSc1,
- Devarshi Vasa1,
- Muhammad A. Parvaz, PhD1,
- Lucas C. Parra, PhD4,
- Nelly Alia-Klein, PhD1 and
- Rita Z. Goldstein, PhD1,*
- 1Psychiatry and Neuroscience Department, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
- 2Soterix Medical Inc. New York City, NY, USA
- 3Program of Post-Graduation in Physiological Sciences, Federal University of Espirito Santo, Vitoria-ES, Brazil
- 4Biomedical Engineering Department, City College of New York, New York City, NY, USA
- ↵*Corresponding author:
Rita Z. Goldstein, PhD, Professor, Department of Psychiatry (primary) and Department of Neuroscience (secondary), Chief, Neuropsychoimaging of Addiction and Related Conditions (NARC) Research Program, Icahn School of Medicine, Gustave L. Levy Place, Box 1230, New York, NY 10029, Tel: 212-659-8886, rita.goldstein{at}mssm.edu
Posted October 13, 2020.
A double-blind sham-controlled phase 1 clinical trial of tDCS of the dorsolateral prefrontal cortex in cocaine inpatients: craving, sleepiness, and contemplation to change
